Gilead and Nucleai Expand AI-Powered Tissue Intelligence Collaboration for ADC Biomarker Discovery
核心洞察
Nucleai (搜索) and Gilead Sciences are collaborating to apply AI-powered Tissue Intelligence to Gilead's global antibody-drug conjugate (ADC) clinical development programs across multiple oncology indications.
The collaboration has analyzed large datasets of H&E and IHC whole-slide images from several Gilead clinical studies, generating candidate spatial biomarkers for future scientific presentations and publications.
Nucleai (搜索)'s platform integrates computational pathology, spatial biology, and clinical outcomes data to map protein expression patterns, tumor heterogeneity, and the tumor microenvironment.
Gilead Sciences has expanded its biomarker discovery capabilities through an ongoing translational research collaboration with Israel-based Nucleai (搜索), applying the company's AI-powered Tissue Intelligence platform to support Gilead's global antibody-drug conjugate (ADC) clinical development programs across multiple oncology indications.
Under the collaboration, Nucleai (搜索) has analyzed large datasets of hematoxylin and eosin (H&E) and immunohistochemistry (IHC) whole-slide images drawn from several of Gilead's clinical studies. The platform integrates computational pathology, spatial biology, and clinical outcomes data to extract quantitative tissue features — mapping protein expression patterns, tumor heterogeneity, and microenvironmental context — and linking those features to patient response data. The work has produced candidate spatial biomarkers intended for future scientific presentations and publications. Financial terms were not disclosed.
"Precision oncology is entering a new phase, where understanding tissue architecture is becoming just as important as understanding molecular alterations," said Avi Veidman, Chief Executive Officer of Nucleai (搜索). "Tissue Intelligence is becoming a foundational capability for precision medicine, helping identify the patients most likely to benefit while enabling pharmaceutical companies to translate tissue biology into reproducible biomarkers that improve the speed and success of oncology drug development."
Integrating Spatial Context into ADC Development
Unlike traditional image analysis approaches, Nucleai (搜索)'s AI-native platform integrates computational pathology, spatial biology, clinical outcomes, and multimodal data into a unified framework. This enables standardized biomarker assessment from preclinical research through late-stage clinical development while revealing mechanisms of response, resistance, and disease progression.
As target expression alone proves insufficient to explain ADC response, Nucleai (搜索)'s Tissue Intelligence platform integrates protein expression with tissue architecture, tumor heterogeneity, and microenvironmental context to better characterize the biological drivers of therapeutic efficacy. The collaboration demonstrates how AI-powered Tissue Intelligence can standardize biomarker analyses while connecting tissue biology to clinical outcomes, creating a scalable foundation for translational research, biomarker development, and precision medicine.
"Scale and reproducibility are becoming essential requirements for biomarker development," said Dr. Ken Bloom, Head of Pathology at Nucleai (搜索). "Our platform enables standardized spatial analyses across thousands of clinical samples while directly linking tissue biology to patient outcomes, generating evidence that can support translational research, biomarker qualification, and future companion diagnostic strategies."
Industry Momentum in AI-Driven Biomarker Discovery
The collaboration extends Nucleai (搜索)'s track record of pharma-facing platform engagements in the ADC space. The company has previously partnered with Bio-Techne Corporation (搜索) on a spatial biology workflow that identified predictive biomarkers in melanoma patients from the SECOMBIT clinical trial, and joined CellCarta (搜索)'s Digital Pathology and AI Consortium alongside six other AI pathology firms in July 2026.
For Gilead, the arrangement adds an AI tissue analytics layer to an ADC pipeline that has expanded aggressively through external transactions, including its acquisition of Germany-based Tubulis (搜索) — which had originated from an exclusive option and license agreement signed in December 2024. A comparable AI-driven biomarker collaboration in the ADC space was struck by Tempus AI and Daiichi Sankyo in March 2026, in which Tempus deployed its PRISM2 multimodal foundation model to support patient stratification for an undisclosed ADC program.
The ongoing collaboration with Gilead and other leading pharmaceutical companies reflects growing industry recognition that AI-powered tissue analytics strengthen biomarker development and precision medicine across oncology portfolios. Nucleai (搜索) continues to expand collaborations with leading pharmaceutical companies to advance biomarker discovery, translational medicine, companion diagnostic development, and AI-powered Tissue Intelligence across the oncology development lifecycle.